Authorities bear down on Indian CROs; Allergan takes its AMD drug into Phase II;

@FierceBiotech: 21st Century drug bill triggers a DC dust-up over relaxed development regs. Report | Follow @FierceBiotech

@JohnCFierce: EuroBiotech: KDEV halves portfolio value, U.K. life sci funding hits 10-year high, CF gene therapy on the block. Report | Follow @JohnCFierce

@DamianFierce: ICYMI: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Release | Follow @DamianFierce

> The FDA and World Health Organization have dialed up their scrutiny of Indian CROs after a pair of alarming study missteps have come to light over the past year. News

> Allergan ($AGN) is launching a Phase III trial of abicipar, a treatment for wet age‐related macular degeneration, triggering a $15 million payment for Molecular Partners, the drug's inventor. More

> Aerie Pharmaceuticals ($AERI) Chief Medical Officer Brian Levy has left the company. Item

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: CombiMatrix coasts toward growth with renewed sales push. Report | Follow @FierceMedDev

@StacyALawrence: Go big or go home: A call for FierceMedicalDevices' 2015 Fierce 15 nominations. ICYMI | Follow @StacyALawrence

@EmilyWFierce: Natera joins forces with University College London for lung cancer study. FierceDiagnostics story | Follow @EmilyWFierce

> Smith & Nephew strikes again, bolstering emerging markets with Russian trauma and orthopedics buy. Story

> Xagenic ropes in $15M for point-of-care testing system. Article

> CMS to test new reimbursement system for hip and knee replacements in the U.S. More

Pharma News

@FiercePharma: ImmuCell boosts Q2 sales guidance as inventory management improves. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: FDA says China staffer Dr. Lixia Wang was key to negotiating deal for more FDA inspection staff in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AstraZeneca grabs $215M for GI drug rights in latest cash-generating deal. Article | Follow @CarlyHFierce

> Novartis' pay-for-performance Entresto plan has its critics--Express Scripts' Miller among them. Story

> U.K. cost gatekeeper changes its tune on Entyvio for Crohn's. More

> Fresenius companies fined £550,000 by U.K. court in patient death. News

Suggested Articles

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.

Immuno-oncology biotech Iovance Biotherapeutics’ shares rocketed up by nearly 40% Tuesday on buyout chatter.